menu
    • menu
    [{"orgOrder":0,"company":"Medicus Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Cytotoxic Drug","year":"2025","type":"Inapplicable","leadProduct":"Doxorubicin Hydrochloride","moa":"DNA | DNA topoisomerase II alpha","graph1":"Oncology","graph2":"Phase II","graph3":"Medicus Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Patch","sponsorNew":"Medicus Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Medicus Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Medicus Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Cytotoxic Drug","year":"2025","type":"Inapplicable","leadProduct":"Doxorubicin Hydrochloride","moa":"DNA | DNA topoisomerase II alpha","graph1":"Oncology","graph2":"Phase II","graph3":"Medicus Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Patch","sponsorNew":"Medicus Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Medicus Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Medicus Pharma","sponsor":"Maxim Group LLC","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Cytotoxic Drug","year":"2024","type":"Public Offering","leadProduct":"Doxorubicin Hydrochloride","moa":"DNA | DNA topoisomerase II alpha","graph1":"Oncology","graph2":"Phase II","graph3":"Medicus Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Patch","sponsorNew":"Medicus Pharma \/ Maxim Group LLC","highestDevelopmentStatusID":"8","companyTruncated":"Medicus Pharma \/ Maxim Group LLC"},{"orgOrder":0,"company":"Medicus Pharma","sponsor":"Maxim Group LLC","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Cytotoxic Drug","year":"2024","type":"Public Offering","leadProduct":"Doxorubicin Hydrochloride","moa":"DNA | DNA topoisomerase II alpha","graph1":"Oncology","graph2":"Phase II","graph3":"Medicus Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Patch","sponsorNew":"Medicus Pharma \/ Maxim Group LLC","highestDevelopmentStatusID":"8","companyTruncated":"Medicus Pharma \/ Maxim Group LLC"},{"orgOrder":0,"company":"Medicus Pharma","sponsor":"Swanielle Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Cytotoxic Drug","year":"2024","type":"Collaboration","leadProduct":"Doxorubicin Hydrochloride","moa":"DNA | DNA topoisomerase II alpha","graph1":"Oncology","graph2":"Phase II","graph3":"Medicus Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Patch","sponsorNew":"Medicus Pharma \/ Swanielle Inc","highestDevelopmentStatusID":"8","companyTruncated":"Medicus Pharma \/ Swanielle Inc"},{"orgOrder":0,"company":"Medicus Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Cytotoxic Drug","year":"2025","type":"Inapplicable","leadProduct":"Doxorubicin Hydrochloride","moa":"DNA | DNA topoisomerase II alpha","graph1":"Oncology","graph2":"Phase II","graph3":"Medicus Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Patch","sponsorNew":"Medicus Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Medicus Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Medicus Pharma","sponsor":"YA II PL","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Peptide, Unconjugated","year":"2025","type":"Financing","leadProduct":"Teverelix Trifluoroacetate","moa":"GnRH receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Medicus Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Medicus Pharma \/ YA II PL","highestDevelopmentStatusID":"8","companyTruncated":"Medicus Pharma \/ YA II PL"},{"orgOrder":0,"company":"Medicus Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Cytotoxic Drug","year":"2025","type":"Inapplicable","leadProduct":"Doxorubicin Hydrochloride","moa":"DNA | DNA topoisomerase II alpha","graph1":"Oncology","graph2":"Phase II","graph3":"Medicus Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Patch","sponsorNew":"Medicus Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Medicus Pharma \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by Medicus Pharma

    Menu

    Medicus Pharma

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Medicus Pharma

                            Canada arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            Medicus Pharma

                            Canada arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Doxorubicin Hydrochloride

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Medicus Pharma Ltd. Treats First Patient in UAE SKNJCT-004 BCC Study

                            Details : Doxorubicin HCl, a cytotoxic drug targeting DNA topoisomerase II alpha, shows promise in treating Basal cell carcinoma (BCC) of the skin.

                            Product Name : D-MNA

                            Product Type : Cytotoxic Drug

                            Upfront Cash : Inapplicable

                            October 22, 2025

                            Lead Product(s) : Doxorubicin Hydrochloride

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Medicus Pharma

                            Canada arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            Medicus Pharma

                            Canada arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Teverelix Trifluoroacetate

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : YA II PL

                            Deal Size : Undisclosed

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Medicus Pharma Ltd. Announces $8.0 Million Non-Dilutive Debenture Financing

                            Details : The proceeds will be used to accelerate the development of Teverelix, a next generation GnRH Antagonist, as a first in class market product for AURr and high CV risk Prostate Cancer.

                            Product Name : Undisclosed

                            Product Type : Peptide, Unconjugated

                            Upfront Cash : Undisclosed

                            September 18, 2025

                            Lead Product(s) : Teverelix Trifluoroacetate

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : YA II PL

                            Deal Size : Undisclosed

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Medicus Pharma

                            Canada arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            Medicus Pharma

                            Canada arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Doxorubicin Hydrochloride

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Medicus’ SKNJCT-003 Shows Positive Interim Data in Basal Cell Carcinoma

                            Details : D-MNA (doxorubicin) is a dissolvable transdermal patch featuring cellulose-based microneedle arrays loaded with doxorubicin. It is being evaluated for the treatment of nodular basal cell carcinoma.

                            Product Name : D-MNA

                            Product Type : Cytotoxic Drug

                            Upfront Cash : Inapplicable

                            March 06, 2025

                            Lead Product(s) : Doxorubicin Hydrochloride

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Medicus Pharma

                            Canada arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            Medicus Pharma

                            Canada arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Doxorubicin Hydrochloride

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Medicus Pharma Submits Phase 2 SKNJCT-004 Design for UAE BCC Treatment

                            Details : D-MNA (doxorubicin) is a dissolvable transdermal patch featuring cellulose-based microneedle arrays loaded with doxorubicin. It is being evaluated for the treatment of nodular basal cell carcinoma.

                            Product Name : D-MNA

                            Product Type : Cytotoxic Drug

                            Upfront Cash : Inapplicable

                            February 27, 2025

                            Lead Product(s) : Doxorubicin Hydrochloride

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Medicus Pharma

                            Canada arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            Medicus Pharma

                            Canada arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Doxorubicin Hydrochloride

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Medicus Updates SKNJCT-003 Phase 2 Study for Nodular Basal Cell Carcinoma

                            Details : D-MNA (doxorubicin) is a dissolvable transdermal patch featuring cellulose-based microneedle arrays loaded with doxorubicin. It is being evaluated for the treatment of nodular basal cell carcinoma.

                            Product Name : D-MNA

                            Product Type : Cytotoxic Drug

                            Upfront Cash : Inapplicable

                            February 14, 2025

                            Lead Product(s) : Doxorubicin Hydrochloride

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Medicus Pharma

                            Canada arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            Medicus Pharma

                            Canada arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Doxorubicin Hydrochloride

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Swanielle Inc

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Medicus Pharma Expands Phase 2 Study Collaboration in Asia Pacific

                            Details : The collaboration aims to explore expansion of Phase 2 clinical study evaluating D-MNA, microneedle arrays containing doxorubicin for treatment of Basal Cell Carcinoma in the Asia-pacific region.

                            Product Name : D-MNA

                            Product Type : Cytotoxic Drug

                            Upfront Cash : Undisclosed

                            December 02, 2024

                            Lead Product(s) : Doxorubicin Hydrochloride

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Swanielle Inc

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Medicus Pharma

                            Canada arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            Medicus Pharma

                            Canada arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Doxorubicin Hydrochloride

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Maxim Group LLC

                            Deal Size : $4.0 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Medicus Pharma Raises $4.0M Through Initial Public Offering in the United States

                            Details : The Company intends to use the proceeds to fund its Phase 2 proof of concept trial for basal cell carcinoma using its doxorubicin tip loaded dissolvable microarray needle skinpatch, D-MNA.

                            Product Name : D-MNA

                            Product Type : Cytotoxic Drug

                            Upfront Cash : Undisclosed

                            November 19, 2024

                            Lead Product(s) : Doxorubicin Hydrochloride

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Maxim Group LLC

                            Deal Size : $4.0 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Medicus Pharma

                            Canada arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            Medicus Pharma

                            Canada arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Doxorubicin Hydrochloride

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Maxim Group LLC

                            Deal Size : $4.0 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Medicus Pharma Raises $4.0M in U.S. Initial Public Offering for Pipeline Growth

                            Details : The Company intends to use the proceeds to fund its Phase 2 proof of concept trial for basal cell carcinoma using its doxorubicin tip loaded dissolvable microarray needle skinpatch, D-MNA.

                            Product Name : D-MNA

                            Product Type : Cytotoxic Drug

                            Upfront Cash : Undisclosed

                            November 13, 2024

                            Lead Product(s) : Doxorubicin Hydrochloride

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Maxim Group LLC

                            Deal Size : $4.0 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth